Skip to main content

Halozyme Therapeutics, Inc. (HALO) Stock Analysis

Falling Knife setup · Temp Headwind edge

Buy WaitVALUE-TRAP 2/5Moderate Confidence

Healthcare · Biotechnology

Earnings in 5 days (2026-05-05). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Wait for pullback to $62.31. Weak momentum — blocks BUY_NOW at $63.76. Engine's entry $62.31 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Leverage penalty (D/E 44.6): -1.5; Earnings in 5 days (event risk).

Halozyme is a biopharmaceutical company licensing its ENHANZE drug delivery technology to pharma partners, enabling subcutaneous delivery of biologics. Revenue comes from licensing fees, milestones, and royalties on 10 commercially approved partner products across 13... Read more

$63.76+18.0% A.UpsideScore 6.5/10#8 of 158 Biotechnology
Entry $62.31(Support Atr Sticky)Stop $58.37Target $74.63(analyst − 13%)A.R:R 2.8:1Setup A.R:R 4.0:1
Analyst target$85.78+34.5%9 analysts
$74.63our TP
$63.76price
$85.78mean
$57
$96

Wait for pullback to $62.31. Weak momentum — blocks BUY_NOW at $63.76. Engine's entry $62.31 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Leverage penalty (D/E 44.6): -1.5; Earnings in 5 days (event risk). Chart setup: Death cross, below all MAs, RSI 35, MACD bearish. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.02, quality 8.6/10, growth 10.0/10). Score 6.5/10, moderate confidence.

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.80, semi cycle peak clear). Fails on weak momentum and earnings proximity 5d<=7d. Suitability: moderate.

Val7.8Qual8.6Grw10.0Mom1.3Sent7.5Ins3.3Peer5.3Tech7.1Risk4.56.5OVERALL

Thesis

Rewards
Strong earnings beat streak (3/4)
High-quality business
Attractive valuation
Risks
Leverage penalty (D/E 44.6): -1.5
Earnings in 5 days (event risk)
Negative momentum

Key Metrics

P/E (TTM)24.6
P/E (Fwd)6.4
Mkt Cap$7.5B
EV/EBITDA10.6
Profit Mgn22.7%
ROE153.6%
Rev Growth51.6%
Beta1.03
DividendNone
Rating analysts15

Quality Signals

Piotroski F8/9

Options Flow

P/C0.25bullish
IV54%elevated
Max Pain$35-45.1% vs spot

Material Events(8-K, last 90d)

  • 2026-03-12Item 5.02HIGH
    David Ramsay appointed Interim CFO effective March 23, 2026. Previously served as Company CFO 2003-2009 and 2013-2015. No permanent CFO successor named; prior permanent CFO departure not described in this filing.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker·2 ceiling hits

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Volume
0.0
Obv
1.0
Ma Position
2.2
Rsi
3.5
Volume distribution (falling OBV)Below 200-MA but MA still rising (+2.5%/30d) — pullback in uptrend, not confirmed weakness
GatesMomentum 1.3<4.5EARNINGS PROXIMITY 5d<=7dA.R:R 2.8 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.80SEMI CYCLE PEAK CLEARFalling KnifeSuitability: Moderate
RSI
35 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $62.27Resistance $70.32

Price Targets

$58
$62
$75
A.Upside+17.0%
A.R:R2.8:1
Setup A.R:R (at entry)4.0:1

Position Sizing

ConvictionHigh conviction
Suggested %0.8%
Max %1.7%
RegimeCautious

Risk Alerts

! Momentum score 1.3/10 — below 4.5 minimum
! EARNINGS_PROXIMITY:5d<=7d

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-05-05 (5d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is HALO stock a buy right now?

Wait for pullback to $62.31. Weak momentum — blocks BUY_NOW at $63.76. Engine's entry $62.31 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Leverage penalty (D/E 44.6): -1.5; Earnings in 5 days (event risk). Chart setup: Death cross, below all MAs, RSI 35, MACD bearish. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.02, quality 8.6/10, growth 10.0/10). Target $74.63 (+17.0%), stop $58.37 (−9.2%), Setup A.R:R 4.0:1. Score 6.5/10, moderate confidence.

What is the HALO stock price target?

Take-profit target: $74.63 (+18.0% upside). Target $74.63 (+17.0%), stop $58.37 (−9.2%), Setup A.R:R 4.0:1. Stop-loss: $58.37.

What are the risks of investing in HALO?

Leverage penalty (D/E 44.6): -1.5; Earnings in 5 days (event risk); Negative momentum.

Is HALO overvalued or undervalued?

Halozyme Therapeutics, Inc. trades at a P/E of 24.6 (forward 6.4). TrendMatrix value score: 7.8/10. Verdict: Buy (Wait for Entry).

What do analysts say about HALO?

15 analysts cover HALO with a consensus score of 3.8/5. Average price target: $86.

What does Halozyme Therapeutics, Inc. do?Halozyme is a biopharmaceutical company licensing its ENHANZE drug delivery technology to pharma partners, enabling...

Halozyme is a biopharmaceutical company licensing its ENHANZE drug delivery technology to pharma partners, enabling subcutaneous delivery of biologics. Revenue comes from licensing fees, milestones, and royalties on 10 commercially approved partner products across 13 collaborations. Roche is the largest partner with 5 approved products.

Related stocks: NVAX (Novavax, Inc.) · HRMY (Harmony Biosciences Holdings, I) · INCY (Incyte Corporation) · CPRX (Catalyst Pharmaceuticals, Inc.) · INVA (Innoviva, Inc.)